Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HarBin Medical Univ. c-Myc G-quadruplex compound X3
- Development stage
- Unknown
- Lead developer
- Harbin Medical University
01
Overview
HarBin Medical Univ. c-Myc G-quadruplex compound X3: sourced facts only. name: "On this basis, compound X3 with higher c-Myc G4 selectivity was developed." [PMID:40262296]; target: "On this basis, compound X3 with higher c-Myc G4 selectivity was developed." [PMID:40262296]; developer: "Department of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, HarBin Medical University, Harbin, 150081, China." [PMID:40262296]
02
Targets
MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on HarBin Medical Univ. c-Myc G-quadruplex compound X3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HarBin Medical Univ. c-Myc G-quadruplex compound X3.